We build AI tools and research services for pharma teams and investors. Our team works from San Francisco and Dubai.
AI researchers and pharma professionals working together
Leadership
Andrey Doronichev
CEO
Previously Director of Product, Google
Luba Greenwood, J.D.
President
Previously Roche, Pfizer, Google
Vlad Vinogradov
VP, AI
Previously Intel, Beiersdorf, Eora
Roman Doronin
VP, Engineering
Previously Eora Data Lab
Ilya Yasny, PhD
Scientific due diligence
Previously Inbio
Dmitry Kobyzev, PhD
Commercial due diligence
Previously PwC
Backed by
From evaluating drug assets to planning a launch
Live today
Scout
Identify drug assets that meet your scientific and commercial criteria.
Evaluate
Review the evidence, compare assets, and identify risks and open questions.
Launch
Compare positioning options, map patient journeys, and review market data to support launch planning.
Planned capabilities
Grow
Track market share, treatment uptake, and competitor activity.
Defend
Plan for loss of exclusivity with research on potential market entrants.
We improve our research workflows through evaluation and expert feedback. Our agreements with each client define how we use and protect their data.
Where we came from
Our roots in drug discovery
We started by building models to search large compound libraries, working with academic collaborators and publishing the methods and results.
That work also showed us how much research goes into choosing drug assets, indications, and markets. We applied our experience in AI and scientific evaluation to these questions, building tools for the commercial side of pharma.